STVN — Stevanato Group S.p.A.

Summary of Stevanato Group (STVN) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Grew 8% year-over-year to EUR 302 million, with the Biopharmaceutical and Diagnostic Solutions (BDS) segment increasing by 9%. The Engineering segment saw a slight decline of 2%.
• High-Value Solutions: Revenue from high-value solutions rose 16% to EUR 135.9 million, accounting for 45% of total revenue.
• Gross Profit Margin: Increased by 60 basis points to 28.7%. Adjusted operating profit margin rose 250 basis points to 18%.
• Net Profit: Totaled EUR 23 million, with diluted earnings per share at EUR 0.08. Adjusted net profit increased 20% to EUR 37.6 million, with adjusted diluted EPS at EUR 0.14.
• Adjusted EBITDA: Increased 21% to EUR 78.7 million, with an adjusted EBITDA margin of 26%.
• Cash Position: Ended the quarter with EUR 78.6 million in cash and cash equivalents and net debt of EUR 360.3 million.

2. Strategic Updates and Business Highlights

• Divestiture: Completed the sale of Balda C. Brewer, a California-based subsidiary, which was not aligned with the company’s focus on biologics and integrated drug delivery systems. This divestiture is expected to be margin-accretive.
• Product Development: Regulatory approval received for the Alina variable dose pen platform in several European countries, marking a significant milestone. The company is also developing the Deora, a multi-use fixed-dose pen injector.
• Market Positioning: Strong demand for injectable biologics, with over 9,000 assets in the global drug pipeline, 60% of which are biologics. The company is focusing on high-value biologics and integrated drug delivery systems.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated full-year revenue expected to be between EUR 1.260 billion and EUR 1.280 billion, reflecting a reduction due to the divestiture but offset by better-than-anticipated currency translation and organic growth.
• Adjusted EBITDA: Expected to be between EUR 335 million and EUR 345.2 million.
• High-Value Solutions: Anticipated to comprise 47% to 48% of total company revenue.
• Engineering Segment: Expected to decline by mid-single digits to low double digits.

4. Bad News, Challenges, or Points of Concern

• Engineering Segment Decline: The Engineering segment reported a 2% revenue decline, attributed to lower sales in pharma visual inspection and glass converting.
• Tax Rate Increase: The effective tax rate increased due to the absence of prior year incentives and the lack of tax benefits from the divestiture.
• Negative Free Cash Flow: Reported negative free cash flow of EUR 32 million for the quarter, driven by high capital expenditures related to growth investments.

5. Notable Q&A Insights

• BDS Growth Outlook: The BDS segment's growth guidance was adjusted to high single digits, primarily due to the divestiture impact, though organic growth remains strong.
• GLP-1 Market: While GLP-1s are a significant growth driver, the company emphasized its broader focus on biologics, with a substantial pipeline of injectable assets.
• Alina Product: The approval of Alina is expected to generate double-digit revenue growth in the coming years, with significant traction anticipated from biosimilars.
• Engineering Segment Recovery: The management expressed cautious optimism about improving order intake and backlog, although sales cycles remain elongated.

Overall, Stevanato Group's Q2 2026 results reflect solid revenue growth and strategic positioning in the biologics market, despite challenges in the Engineering segment and the impact of the recent divestiture. The company remains focused on high-value solutions and integrated drug delivery systems as key growth drivers.